What is the 13F Pro Quality Score for BRTX?

13F Pro ranks BioRestorative Therapies, Inc. (BRTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BRTX's current score at https://13fpro.ai/research/BRTX (free sign-up required for the full ranking).

Which hedge funds own the most BRTX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BRTX include CITADEL ADVISORS, GEODE CAPITAL MANAGEMENT,, UBS Group AG. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/BRTX as soon as new 13F filings post.

Where does 13F Pro source BRTX data?

All BioRestorative Therapies, Inc. fundamentals and ownership data come directly from SEC EDGAR. BioRestorative Therapies, Inc. files with the SEC under CIK 1505497. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BRTX in?

BioRestorative Therapies, Inc. (BRTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BRTX research updated on 13F Pro?

BRTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BioRestorative Therapies, Inc.(BRTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1505497 BRTX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.6M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

BRTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BioRestorative Therapies, Inc. (BRTX), a Healthcare sector company. BRTX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.6m in revenue. Based on the latest XBRL financial filings (Q1 2026), BioRestorative Therapies, Inc. reports quarterly revenue of $23.2K, net income of $-2.2M, free cash flow of $-3.8M. Top institutional holders of BRTX by reported 13-F value include CITADEL ADVISORS, GEODE CAPITAL MANAGEMENT,, UBS Group AG, based on the most recent SEC filings. BRTX trades on the Nasdaq exchange and files with the SEC under CIK 1505497. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BRTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioRestorative Therapies, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$23.2K

Net Income

Q1 2026

$-2.2M

Free Cash Flow

Q1 2026

$-3.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-10.3% YoY

$359.7KFY 2025

FY22 $119.8KFY23 $145.8KFY24 $401.0KFY25 $359.7K

Net Income

-58.6% YoY

$-14.2MFY 2025

FY22 $-13.2MFY23 $-10.4MFY24 $-9.0MFY25 $-14.2M

Operating Income

-35.4% YoY

$-15.6MFY 2025

FY22 $-19.0MFY23 $-15.2MFY24 $-11.6MFY25 $-15.6M

EPS (Diluted)

-36.2% YoY

$-0.53FY 2025

FY22 $-1.22FY23 $-0.82FY24 $-0.39FY25 $-0.53

Total Assets

-66.8% YoY

$4.1MFY 2025

FY22 $16.4MFY23 $12.6MFY24 $12.3MFY25 $4.1M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

-31.1% YoY

$-10.8MFY 2025

FY22 $-5.9MFY23 $-6.4MFY24 $-8.2MFY25 $-10.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$359.7K -10.3%	$401.0K +175.0%	$145.8K +21.7%	$119.8K +160.4%	$46.0K -64.6%	$130.0K
Net Income	$-14.2M -58.6%	$-9.0M +13.8%	$-10.4M +21.2%	$-13.2M +70.2%	$-44.3M -202.5%	$-14.6M
Operating Income	$-15.6M -35.4%	$-11.6M +24.1%	$-15.2M +19.8%	$-19.0M +27.9%	$-26.3M -212.0%	$-8.4M
EPS (Diluted)	$-0.53 -36.2%	$-0.39 +53.0%	$-0.82 +32.3%	$-1.22	—	—
Total Assets	$4.1M -66.8%	$12.3M -2.6%	$12.6M -23.3%	$16.4M -26.8%	$22.5M +1431.3%	$1.5M
Total Debt	—	—	—	—	$250.0K	—
Operating Cash Flow	$-10.8M -31.1%	$-8.2M -28.0%	$-6.4M -8.7%	$-5.9M -77.6%	$-3.3M +51.9%	$-6.9M

AI Insight: BRTX Financial Trends

BRTX remains pre-revenue with persistent operating losses; equity eroded to near-zero by Q4 2025 before slight recovery.

• Revenue remains at $0M across all eight quarters; company has generated no commercial sales since Q2 2024.

• Net loss improved to $2M in Q1 2026 from peak of $5M in Q1 2025, but operating cash burn persists at $2M–$4M quarterly.

• Shareholder equity collapsed from $11M (Q2 2024) to $0M (Q4 2025), indicating cumulative losses consumed all book value.

⚠ Equity rebounded to $3M in Q1 2026 after hitting zero—source unclear; watch for dilutive financing or accounting adjustments.

⚠ Operating cash outflow accelerated to $4M in Q1 2026 despite improved net loss, signaling cash runway depletion risk.

AI Insight: BRTX Ratio Trends

Data too sparse to assess trends; only Q2–Q4 2024 show negative returns, all other periods missing.

• Q2 2024 showed severe negative returns: ROE −149.2%, ROA −100.0%, ROIC −91.5%.

• Q3 2024 showed partial recovery in ROE (−43.7%) and ROA (−30.0%), though ROIC unchanged at −91.5%.

⚠ No profitability or efficiency metrics reported for Q1 2025 onward; inability to assess current operational performance.

⚠ Persistent negative ROIC in Q2–Q3 2024 suggests value destruction; recovery status unknown due to data gaps.

Get alerted when BRTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BioRestorative Therapies, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BRTX

CITADEL ADVISORS LLC
$64.9K238,606 sh
GEODE CAPITAL MANAGEMENT, LLC
$60.7K223,083 sh
UBS Group AG
$27.2K99,832 sh
WEALTH ALLIANCE, LLC
$10.9K40,000 sh
VANGUARD FIDUCIARY TRUST CO
$10.7K39,452 sh
STATE STREET CORP
$8.8K32,459 sh
OSAIC HOLDINGS, INC.
$540.002,000 sh
Tower Research Capital LLC (TRC)
$398.001,462 sh
SBI Securities Co., Ltd.
$54.00199 sh
TD Waterhouse Canada Inc.
$1.003 sh

Fund	Value	Shares
CITADEL ADVISORS LLC	$64.9K	238,606
GEODE CAPITAL MANAGEMENT, LLC	$60.7K	223,083
UBS Group AG	$27.2K	99,832
WEALTH ALLIANCE, LLC	$10.9K	40,000
VANGUARD FIDUCIARY TRUST CO	$10.7K	39,452
STATE STREET CORP	$8.8K	32,459
OSAIC HOLDINGS, INC.	$540.00	2,000
Tower Research Capital LLC (TRC)	$398.00	1,462
SBI Securities Co., Ltd.	$54.00	199
TD Waterhouse Canada Inc.	$1.00	3

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BRTX on your watchlist

Track score changes the day BioRestorative Therapies, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BRTX a good stock to buy?

13F Pro's AI-powered analysis of BioRestorative Therapies, Inc. (BRTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BRTX are available on the BRTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BRTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BRTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BioRestorative Therapies, Inc.'s investment landscape.